- Titre
- Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France
- Créateurs - sans rôle
- Maurice Pérol - Department of Medical Oncology, Centre Léon Bérard, Lyon, FranceClarisse Audigier-Valette - Department of Thoracic Oncology, Hôpital Sainte Musse, Toulon, FranceHervé Léna - Centre hospitalier universitaire Pontchaillou, Rennes, FranceMarie-Ange Massiani - Department of Medical Oncology, Institut Curie, Saint-Cloud, FranceXavier Quantin - Institut du Cancer de Montpellier, Montpellier, FranceMelissa Santorelli - Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USAMarion Apert - Outcomes Research, MSD France, Puteaux, FranceAxelle Spampinato - Medical Affairs, MSD France, Puteaux, FranceThomas Burke - Outcomes Research, MRL, Merck & Co. Inc., Rahway, NJ, USAChristos Chouaid - Pneumonology Unit, Centre Hospitalier Intercommunal, Créteil, France
- Détails de publication
- Respiratory medicine and research, Vol.89, p.101238
- Éditeur
- Elsevier Masson SAS
- Identifiants
- 99162823009311
- Unité académique
- Institut de Recherche en Cancérologie de Montpellier - IRCM
- Langue
- English
- Type de ressource
- Journal article
Article de revue
Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France
Respiratory medicine and research, Vol.89, p.101238
05/2026
PMID: 41468718
Indicateurs
1 Consultations de la notice